Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

108
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
108
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.3K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

126
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
126
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

135
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
135
Hepatic Portal System01:21

Hepatic Portal System

4.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
4.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

110
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
110

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence for predicting hospital admissions from the emergency department: a prospective, quasi-experimental study.

Nature communications·2026
Same author

Characteristics and outcomes among patients with stercoral colitis - a retrospective cohort study.

Postgraduate medicine·2026
Same author

External validation of ECG artificial intelligence for emergency and cardiac assessment across a large-scale U.S. healthcare system.

NPJ digital medicine·2026
Same author

Erratum: Clinically relevant cut-points for changes in the Liver Frailty Index are associated with waitlist mortality in patients with cirrhosis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Erratum: The Liver Frailty Index enhances mortality risk prediction above and beyond MELD 3.0 alone.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

ACG Clinical Guideline: Hepatic Encephalopathy.

The American journal of gastroenterology·2026

Related Experiment Video

Updated: Dec 15, 2025

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System
05:43

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System

Published on: October 21, 2022

2.9K

The Current Hepatic Encephalopathy Pipeline.

Alexander J Ryu1, Robert S Rahimi2, Michael D Leise3

  • 1Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, United States.

Journal of Clinical and Experimental Hepatology
|July 14, 2020
PubMed
Summary

Investigational therapies for hepatic encephalopathy (HE) are emerging, targeting gut bacteria and ammonia pathways. Novel treatments beyond lactulose are being explored in ongoing clinical trials for this liver failure complication.

Keywords:
CHESS, clinical hepatic encephalopathy staging scaleFMT, fecal microbiota transplantHE, hepatic encephalopathyHESA, hepatic encephalopathy scoring algorithmMAD, multiple-ascending doseMES, modified encephalopathy scaleORT, object recognition testPEG, polyethylene glycol-3350SAD, single-ascending doseSEV, saccadic eye velocityammoniaantibioticsfecal microbiota transplanthepatic encephalopathylactulosetherapytrials

More Related Videos

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

2.1K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.6K

Related Experiment Videos

Last Updated: Dec 15, 2025

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System
05:43

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System

Published on: October 21, 2022

2.9K
Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

2.1K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.6K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Neuroscience

Background:

  • Hepatic encephalopathy (HE) is a complex complication of liver failure.
  • Current standard treatment, lactulose, has seen little innovation for decades.
  • Recent advances deepen understanding of HE pathophysiology, revealing new therapeutic targets.

Purpose of the Study:

  • To review contemporary investigational therapies for hepatic encephalopathy (HE).
  • To identify novel treatment strategies beyond established methods.
  • To summarize ongoing research and clinical trials in HE therapeutics.

Main Methods:

  • Conducted a narrative review of HE treatments.
  • Searched the ClinicalTrials.gov database for "hepatic encephalopathy" up to August 29, 2019.
  • Identified six key areas of therapeutic focus for novel HE treatments.

Main Results:

  • Six key areas of investigational HE therapies were identified.
  • These include antibiotics, ammonia scavengers, probiotics, fecal microbiota transplant, steroid modulators, and non-lactulose laxatives.
  • Active clinical trials are underway for all identified therapeutic areas.

Conclusions:

  • Novel therapeutic targets for hepatic encephalopathy are being actively investigated.
  • These emerging treatments address both traditional and newly discovered HE mechanisms.
  • Ongoing trials suggest potential future advancements in HE management.